- Home
- ITRG vs GLSI Comparison
ITRG vs GLSI Comparison
Compare ITRG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- GLSI
- Stock Information
- Founded
- ITRG 1997
- GLSI 2006
- Country
- ITRG Canada
- GLSI United States
- Employees
- ITRG N/A
- GLSI N/A
- Industry
- ITRG Precious Metals
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- GLSI Health Care
- Exchange
- ITRG Nasdaq
- GLSI Nasdaq
- Market Cap
- ITRG 156.9M
- GLSI 143.4M
- IPO Year
- ITRG N/A
- GLSI 2020
- Fundamental
- Price
- ITRG $0.80
- GLSI $12.87
- Analyst Decision
- ITRG Strong Buy
- GLSI Strong Buy
- Analyst Count
- ITRG 1
- GLSI 1
- Target Price
- ITRG $2.00
- GLSI $38.00
- AVG Volume (30 Days)
- ITRG 242.4K
- GLSI 43.0K
- Earning Date
- ITRG 11-13-2024
- GLSI 11-14-2024
- Dividend Yield
- ITRG N/A
- GLSI N/A
- EPS Growth
- ITRG N/A
- GLSI N/A
- EPS
- ITRG N/A
- GLSI N/A
- Revenue
- ITRG N/A
- GLSI N/A
- Revenue This Year
- ITRG N/A
- GLSI N/A
- Revenue Next Year
- ITRG $69.44
- GLSI N/A
- P/E Ratio
- ITRG N/A
- GLSI N/A
- Revenue Growth
- ITRG N/A
- GLSI N/A
- 52 Week Low
- ITRG $0.64
- GLSI $8.00
- 52 Week High
- ITRG $1.28
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- ITRG 27.91
- GLSI 51.89
- Support Level
- ITRG $0.86
- GLSI $11.50
- Resistance Level
- ITRG $0.93
- GLSI $12.84
- Average True Range (ATR)
- ITRG 0.03
- GLSI 0.90
- MACD
- ITRG -0.01
- GLSI 0.09
- Stochastic Oscillator
- ITRG 5.08
- GLSI 59.49
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of highly prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.